Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Circe Mesa"'
Autor:
Rydell Alvarez-Arzola, Nicoló Bancaro, Ping Lai, Giuseppe Attanasio, Laura Pellegrini, Martina Troiani, Manuel Colucci, Simone Mosole, Emiliano Pasquini, Andrea Alimonti, Circe Mesa
Publikováno v:
Cell Communication and Signaling, Vol 21, Iss 1, Pp 1-14 (2023)
Abstract Androgen deprivation therapy (ADT) is a standard therapy for prostate cancer (PCa). Though disseminated disease is initially sensitive to ADT, an important fraction of the patients progresses to castration-resistant prostate cancer (CRPC). F
Externí odkaz:
https://doaj.org/article/09b585dd6d844af980b3fa3079b072be
Autor:
Scott I Abrams, Audry Fernández, Liliana Oliver, Rydell Alvarez, Leslie Pérez, Circe Mesa, Kevin H Eng, Raquel Diaz, Anet Valdés, Sean H Colligan, Michael J Nemeth, Danielle Y F Twum, Olivia Fernández-Medina, Louise M Carlson, Han Yu, Mary L Hensen, Maura L Rábade-Chediak, Luis Enrique Fernández, Kelvin P Lee, Jason B Muhitch
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 9 (2022)
Background Immune suppression is common in neoplasia and a major driver is tumor-induced myeloid dysfunction. Yet, overcoming such myeloid cell defects remains an untapped strategy to reverse suppression and improve host defense. Exposure of bone mar
Externí odkaz:
https://doaj.org/article/47e829035a71457082f388bc215f48d3
Autor:
Rachel Evans, Kelvin Lee, Paul K. Wallace, Mary Reid, Jason Muhitch, Askia Dozier, Circe Mesa, Patricia L. Luaces, Orestes Santos-Morales, Adrienne Groman, Carlos Cedeno, Aileen Cinquino, Daniel T. Fisher, Igor Puzanov, Mateusz Opyrchal, Christos Fountzilas, Tong Dai, Marc Ernstoff, Kristopher Attwood, Alan Hutson, Candace Johnson, Zaima Mazorra, Danay Saavedra, Kalet Leon, Agustin Lage, Tania Crombet, Grace K. Dy
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundCIMAvax-EGF is an epidermal growth factor (EGF)-depleting immunotherapy which has shown survival benefit as a switch maintenance treatment after platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC). The primary objecti
Externí odkaz:
https://doaj.org/article/a11a28ebd42a4001a4ac9b99c18aa754
Autor:
María Eliana Lanio Ruiz, Rady Judith Laborde Quintana, Yoelys Cruz Leal, Luis Enrique Fernández Molina, Oraly Sánchez Ferrás, Anaixis del Valle, Isbel Lopetegui González, María C. Luzardo Lorenzo, Carlos Álvarez Valcárcel, Circe Mesa
Publikováno v:
Anales de la Academia de Ciencias de Cuba, Vol 1, Iss 11 (2021)
Introducción: Las estrategias vacunales para potenciar respuestas de linfocitos T CD8+ citotóxicos (CTL) constituyen un reto debido a la necesidad de favorecer la presentación cruzada de antígenos (Ag) exógenos por las células presentadoras de
Externí odkaz:
https://doaj.org/article/96b1c6bdab7846c294b526c08f81dab1
Autor:
Ana Victoria Casadesús, Claire Deligne, Béré Kadjdiatou Diallo, Katya Sosa, Nathalie Josseaume, Circe Mesa, Kalet León, Tays Hernández, Jean-Luc Teillaud
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Anti-CD20 treatment represents a therapeutic benefit for patients with B-cell lymphomas, although more efficient therapies are needed for refractory or relapsing patients. Among them, the combination of anti-CD20 and IL-2 that induces T cell response
Externí odkaz:
https://doaj.org/article/3bcd9f905d40474e9def20f2e1f193b8
Autor:
Catarina V. Nogueira, Rady J. Laborde, Yoelys Cruz-Leal, M. C. Luzardo, Darren E. Higgins, Lianne Abreu-Butin, Daniel Grubaugh, Audry Fernández, Ieda Maria Longo-Maugéri, Circe Mesa, Fabiola Pazos, María E. Lanio, Luis E. Fernández, Michael N. Starnbach, Mayari Eika Ishimura, Carlos Alvarez, María E. Alonso
Publikováno v:
Molecular Immunology. 131:144-154
Sticholysins (Sts) I and II (StI and StII) are pore-forming proteins (PFPs), purified from the Caribbean Sea anemone Stichodactyla helianthus. StII encapsulated into liposomes induces a robust antigen-specific cytotoxic CD8+ T lymphocytes (CTL) respo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bc6e326aff264a56b8da67d237bc4da
https://doi.org/10.1016/j.molimm.2020.12.032
https://doi.org/10.1016/j.molimm.2020.12.032
Autor:
Liliana Oliver, Rydell Alvarez, Raquel Diaz, Anet Valdés, Sean H Colligan, Michael J Nemeth, Danielle Y F Twum, Audry Fernández, Olivia Fernández-Medina, Louise M Carlson, Han Yu, Kevin H Eng, Mary L Hensen, Maura L Rábade-Chediak, Luis Enrique Fernández, Kelvin P Lee, Leslie Perez, Jason B Muhitch, Circe Mesa, Scott I Abrams
Publikováno v:
Journal for ImmunoTherapy of Cancer. 10:e004710
BackgroundImmune suppression is common in neoplasia and a major driver is tumor-induced myeloid dysfunction. Yet, overcoming such myeloid cell defects remains an untapped strategy to reverse suppression and improve host defense. Exposure of bone marr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e89665126bf3fdb4cd27ce8344f3ea69
https://doi.org/10.1136/jitc-2022-004710
https://doi.org/10.1136/jitc-2022-004710
Autor:
ANM Nazmul H. Khan, Tiffany R. Emmons, William J. Magner, Emad Alqassim, Kelly L. Singel, Jason Ricciuti, Kevin H. Eng, Kunle Odunsi, Thomas B. Tomasi, Kelvin Lee, Scott I. Abrams, Circe Mesa, Brahm H. Segal
Publikováno v:
Cancer immunology, immunotherapy : CII. 71(10)
The ovarian tumor microenvironment (TME) is characterized by the accumulation of immunosuppressive tumor-associated macrophages (TAMs) and granulocytic cells. Very small size particles (VSSP), comprised of the ganglioside NAcGM3 and Neisseria meningi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61f060933e03c8ce2118b94b274d5d41
https://pubmed.ncbi.nlm.nih.gov/35166871
https://pubmed.ncbi.nlm.nih.gov/35166871
Autor:
Béré Kadjdiatou Diallo, Kalet León, Jean-Luc Teillaud, Circe Mesa, Nathalie Josseaume, Ana Victoria Casadesús, Katya Sosa, Tays Hernández, Claire Deligne
Publikováno v:
OncoImmunology
OncoImmunology, Taylor & Francis, 2020, 9 (1), pp.1770565. ⟨10.1080/2162402X.2020.1770565⟩
Oncoimmunology
article-version (VoR) Version of Record
OncoImmunology, 2020, 9 (1), ⟨10.1080/2162402X.2020.1770565⟩
OncoImmunology, Vol 9, Iss 1 (2020)
OncoImmunology, 2020, 9 (1), pp.1770565. ⟨10.1080/2162402X.2020.1770565⟩
OncoImmunology, Taylor & Francis, 2020, 9 (1), pp.1770565. ⟨10.1080/2162402X.2020.1770565⟩
Oncoimmunology
article-version (VoR) Version of Record
OncoImmunology, 2020, 9 (1), ⟨10.1080/2162402X.2020.1770565⟩
OncoImmunology, Vol 9, Iss 1 (2020)
OncoImmunology, 2020, 9 (1), pp.1770565. ⟨10.1080/2162402X.2020.1770565⟩
International audience; Anti-CD20 treatment represents a therapeutic benefit for patients with B-cell lymphomas, although more efficient therapies are needed for refractory or relapsing patients. Among them, the combination of anti-CD20 and IL-2 that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5511e2de422ba7fef2c1dc035b29934
https://hal.archives-ouvertes.fr/hal-02985655
https://hal.archives-ouvertes.fr/hal-02985655
Autor:
Dasha Fuentes, Alejandro Cabezas-Cruz, Circe Mesa, Tania Carmenate, Darel Martínez, Anet Valdés-Zayas, Enrique Montero, Rolando Pérez
Publikováno v:
Journal of Breast Cancer. 25:218
The F3II cell line is a highly invasive variant of mammary carcinoma. Although it is frequently used as a model to evaluate the efficacy of immunotherapy, its impact on the immune system remains poorly understood. The main objectives of this study we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::999d3c60b4ff66e0bae1cd09022b98c2
https://doi.org/10.4048/jbc.2022.25.e18
https://doi.org/10.4048/jbc.2022.25.e18